Abstract:Development of intranasal vaccines for respiratory viruses has gained popularity. However, currently only a live-attenuated influenza vaccine is FDA-approved for intranasal administration. Here, we focused on influenza virus as it circulates seasonally, has pandemic potential, and has vaccine formulations that present hemagglutinin (HA) in different structural arrangements. These display differences have not been correlated with induction of pan-H1 antibodies or shown to provide intranasal protection. Using electron microscopy, biochemistry and animal studies, we identified HA complexes arranged as lipid discs with multiple trimeric HAs displayed along the perimeter, termed spike nanobicelles (SNB). We utilized a structure-guided approach to synthesize in vitro assembled spiked nanobicelles (IA-SNB) from a classical 1934 H1N1 influenza virus. IA-SNBs elicited pan-H1 antibodies and provided protection against antigenically divergent H1N1 viruses via intranasal immunizations. Viral glycoprotein spikes displayed as SNBs could aid in combating antigenic variation and provide innovative intranasal vaccines to aid universal influenza vaccine development.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop an intranasal influenza vaccine that can provide broad protection. Specifically, the research team focused on hemagglutinin (HA), the major glycoprotein on the surface of the influenza virus, and explored the possibility of assembling "spike nanobicelles" (SNB) as vaccine components through a structure - guided approach. This new - type vaccine aims to overcome some limitations of existing influenza vaccines, such as immune escape caused by antigen variation, the need to reformulate the vaccine every year, and the fact that only live - attenuated vaccines are currently approved for intranasal vaccination. The key points of the research include: 1. **Structure - guided design**: Using electron microscopy, biochemical analysis, and animal experiments, the research team discovered a special arrangement of HA complexes, that is, multiple trimeric HAs arranged along the edge on a lipid disc - like structure, called "spike nanobicelles" (SNB). 2. **In vitro assembly**: The research team developed an in vitro assembly method and synthesized spike nanobicelles (IA - SNB) from the classic 1934 H1N1 influenza virus. 3. **Immune effect**: By intranasally immunizing mice, the research team found that IA - SNB can induce a broad H1 antibody response and provide protection against H1N1 viruses with different antigenicities. 4. **Comparison with other vaccines**: The study also compared the intranasal immunization effects of SNB with existing influenza vaccines (such as Flublok and Flumist), and the results showed that SNB has advantages in some aspects. Overall, the goal of this paper is to design and evaluate a new influenza vaccine platform in order to achieve broader and more long - lasting protection effects, especially against influenza viruses with frequent antigen variations. This will not only help deal with seasonal influenza, but may also provide new ideas for the development of a universal influenza vaccine.

Structure-guided assembly of an influenza spike nanobicelle vaccine provides pan H1 intranasal protection

Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus

Structural Vaccinology: Structure-Based Design of Influenza A Virus Hemagglutinin Subtype-Specific Subunit Vaccines.

Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages

Prevention of influenza virus infection and transmission by intranasal administration of a porous maltodextrin nanoparticle-formulated vaccine

A Self-Assembling Nanoparticle: Implications for the Development of Thermostable Vaccine Candidates.

Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli filaments and the highly conserved M2e epitope confers protection against influenza a virus in mice

Intranasal Epitope‐Polymer Vaccine Lodges Resident Memory T Cells Protecting against Influenza Virus

Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge

Intranasal hemagglutinin protein boosters induce robust mucosal immunity and cross-protection against influenza A viral challenge

Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection

An Intranasal Multivalent Epitope-Based Nanoparticle Vaccine Confers Broad Protection against Divergent Influenza Viruses

Layered protein nanoparticles containing influenza B HA stalk induced sustained cross-protection against viruses spanning both viral lineages

Enhancing NA immunogenicity through novel VLP designs

Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus

NK cell membrane/MnO 2 hybrid nanoparticle-adjuvanted intranasal vaccines synergistically boost protective immunity against H1N1 influenza infection

A Single-Component Multilayered Self-Assembling Protein Nanoparticle Vaccine Based on Extracellular Domains of Matrix Protein 2 against Both Influenza A and B

Intranasal Immunization with Influenza VLPs Incorporating Membrane-Anchored Flagellin Induces Strong Heterosubtypic Protection

Single-Dose Intranasal Immunisation with Novel Chimeric H1N1 Expressing the Receptor-Binding Domain of SARS-CoV-2 Induces Robust Mucosal Immunity, Tissue-Resident Memory T Cells, and Heterologous Protection in Mice

Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections

Double-layered protein nanoparticles conjugated with truncated flagellin induce improved mucosal and systemic immune responses in mice